Top

Published in:

01-04-2016 | Case report

Colon cancer chemotherapy for a patient with CDX2-expressing metastatic thymic adenocarcinoma: a case report and literature review

Authors: Akihiko Sawaki, Mikiya Ishihara, Yuji Kozuka, Hiroyasu Oda, Satoshi Tamaru, Yumiko Sugawara, Yoshiki Yamashita, Toshiro Mizuno, Taizo Shiraishi, Naoyuki Katayama

Published in: International Cancer Conference Journal | Issue 2/2016

Abstract

We report the case of a 59-year-old man with thymic adenocarcinoma who was treated with colon cancer chemotherapy. He was referred to our hospital for an anterior mediastinal mass and multiple bone metastases that were found by computed tomography. Needle biopsy of the mediastinal tumor revealed a caudal-type homeobox 2 (CDX2)-positive adenocarcinoma. Neither upper nor lower gastrointestinal endoscopic examinations revealed any evidence of a primary tumor. The patient was administered CapeOX (capecitabine and oxaliplatin) and FOLFIRI (fluorouracil, leucovorin and irinotecan)/cetuximab. He died 6 months after diagnosis. Primary thymic adenocarcinoma was confirmed by autopsy. As far as we know, this is the first report in which colon cancer chemotherapy was used to treat CDX2-positive metastatic thymic adenocarcinoma.

Moser B, Schiefer AI, Janik S, Marx A, Prosch H, Pohl W, Neudert B, Scharrer A, Klepetko W, Mullauer L (2014) Adenocarcinoma of the thymus, enteric type: report of 2 cases, and proposal for a novel subtype of thymic carcinoma. Am J Surg Pathol. doi:10.1097/pas.0000000000000359

Witek ME, Nielsen K, Walters R, Hyslop T, Palazzo J, Schulz S, Waldman SA (2005) The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res 11(24 Pt 1):8549–8556. doi:10.1158/1078-0432.ccr-05-1624 CrossRefPubMed

Varadhachary GR, Karanth S, Qiao W, Carlson HR, Raber MN, Hainsworth JD, Greco FA (2014) Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol 19(3):479–484. doi:10.1007/s10147-013-0583-0 CrossRefPubMed

Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL (2008) Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 9(6):596–599. doi:10.1016/s1470-2045(08)70151-7 CrossRefPubMed

Werling RW, Yaziji H, Bacchi CE, Gown AM (2003) CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27(3):303–310CrossRefPubMed

Jung HY, Cho H, Chung JH, Bae SB, Lee JH, Lee HJ, Jang SH, Oh MH (2015) A rare case of primary tubular adenocarcinoma of the thymus, enteric immunophenotype: a case study and review of the literature. J Pathol Transl Med 49(4):331–334. doi:10.4132/jptm.2015.04.16 CrossRefPubMedPubMedCentral

Kapur P, Rakheja D, Bastasch M, Molberg KH, Sarode VR (2006) Primary mucinous adenocarcinoma of the thymus: a case report and review of the literature. Arch Pathol Lab Med 130(2):201–204PubMed

Maeda D, Ota S, Ikeda S, Kawano R, Hata E, Nakajima J, Mori M, Fukayama M (2009) Mucinous adenocarcinoma of the thymus: a distinct variant of thymic carcinoma. Lung Cancer (Amsterdam, Netherlands) 64(1):22–27. doi:10.1016/j.lungcan.2008.06.019 CrossRef

Abdul-Ghafar J, Yong SJ, Kwon W, Park IH, Jung SH (2012) Primary thymic mucinous adenocarcinoma: a case report. Korean J Pathol 46(4):377–381. doi:10.4132/KoreanJPathol.46.4.377 CrossRefPubMedPubMedCentral

10.

Teramoto K, Kawaguchi Y, Hori T, Ishida M, Hashimoto M, Kitamura S, Motoishi M, Hanaoka J, Tezuka N, Okabe H (2012) Thymic papillo-tubular adenocarcinoma containing a cyst: report of a case. Surg Today 42(10):988–991. doi:10.1007/s00595-012-0161-5 CrossRefPubMed

11.

Maghbool M, Ramzi M, Nagel I, Bejarano P, Siebert R, Saeedzadeh A, Daneshbod Y (2013) Primary adenocarcinoma of the thymus: an immunohistochemical and molecular study with review of the literature. BMC Clin Pathol 13(1):17. doi:10.1186/1472-6890-13-17 CrossRefPubMedPubMedCentral

Title: Colon cancer chemotherapy for a patient with CDX2-expressing metastatic thymic adenocarcinoma: a case report and literature review
Authors: Akihiko Sawaki
Mikiya Ishihara
Yuji Kozuka
Hiroyasu Oda
Satoshi Tamaru
Yumiko Sugawara
Yoshiki Yamashita
Toshiro Mizuno
Taizo Shiraishi
Naoyuki Katayama
Publication date: 01-04-2016
Publisher: Springer Japan
Published in: International Cancer Conference Journal / Issue 2/2016
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-015-0239-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Cryptogenic repetitive severe colitis after ileostomy closure

A case report of recurrent adult-onset xanthogranuloma: is the radiotherapy a treatment option?

Primary diffuse large B cell lymphoma of the common bile duct causing obstructive jaundice

Marked improvement in leptomeningeal carcinomatosis and spinal cord metastases following alectinib treatment of crizotinib-resistant, ALK-positive lung adenocarcinoma

Mucosa-associated lymphoid tissue lymphoma involving the kidney: a case report and review of the literature

Spontaneously metachronous ruptures of adrenocortical carcinoma and its contralateral adrenal metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer